Preclinical Investigations of PM01183 (Lurbinectedin) as a Single Agent or in Combination with Other Anticancer Agents for Clear Cell Carcinoma of the OvaryRyoko Takahashi(Osaka University), Tadashi Kimura(Osaka University)PLoS ONEMarch 17, 201610.1371/journal.pone.0151050Cited by 34SaveCiteExport RISWatch citationsRelated PapersInterleukin 6 Receptor Is an Independent Prognostic Factor and a Potential Therapeutic Target of Ovarian Cancer|PLoS ONE|2015|80Prostaglandin E2 produced by myeloid-derived suppressive cells induces cancer stem cells in uterine cervical cancer|Oncotarget|2018|64